At the news
? NEUTRALIMPACT 3/10 6-K filed Jul 13, 2026 at 06:00 ET
Evaxion announced new preclinical data for its CMV vaccine program EVX-V1, presented at an industry conference. The data shows AI-discovered T-cell epitopes improved control of acute infection, latency, and reactivation in mice, supporting the multi-component vaccine concept. This is an early-stage scientific update with no clinical data or regulatory milestone, and the stock has historically declined on similar neutral-content filings.
- New preclinical data for EVX-V1 presented at International Herpesvirus Workshop 2026 in Montreal
- Data show AI-discovered novel T-cell epitopes improved control of acute infection, latency, and reactivation in CMV-infected mice
- EVX-V1 combines novel AI-discovered B-cell and T-cell antigens with AI-optimized versions of established CMV antigens
- No licensed CMV vaccine currently exists; CMV treatment market valued at $474.6M in 2023, CAGR 6.6%
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access